Safety and short-term effectiveness of blinatumomab in the treatment of childhood relapsed/refractory acute lymphoblastic leukemia

• Published in: Zhongguo dang dai er ke za zhi Vol. 25; no. 4; p. 374
• Main Authors: Li, Xiao-Lan, Liu, Li-Peng, Liu, Fang, Guo, Ye, Chen, Xiao-Juan, Zhu, Xiao-Fan, Yang, Wen-Yu
• Format: Journal Article
• Language: Chinese
• Published: China 15.04.2023
• Subjects: Adolescent; Antibodies, Bispecific - adverse effects; Antineoplastic Agents; Child; Female; Humans; Male; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Retrospective Studies; Safety; Short-term effectiveness; Relapsed/refractory acute lymphoblastic leukemia; Child; Blinatumomab
• ISSN: 1008-8830
• DOI: 10.7499/j.issn.1008-8830.2210114

To study the safety and short-term effectiveness of blinatumomab in the treatment of childhood relapsed/refractory acute lymphoblastic leukemia (R/R-ALL). Six children with R/R-ALL who received blinatumomab treatment from August 2021 to August 2022 were included as subjects, and a retrospective analysis was performed for their clinical data. Among the six children, there were three boys and three girls, with a median age of 10.5 (5.0-13.0) years at the time of inclusion. Of all six children, one had refractory ALL and did not achieve remission after several times of chemotherapy, and 5 relapsed for the first time, with a median time of 30 (9-60) months from diagnosis to relapse. Minimal residual disease (MRD) before treatment was 15.50% (0.08%-78.30%). Three children achieved complete remission after treatment, among whom two had negative conversion of MRD. Five children had cytokine release syndrome (CRS), among whom 3 had grade 1 CRS and 2 had grade 2 CRS. Four children were bridged to allogeneic hematopoie